Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$50 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-3 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.7
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
15,447,500
CFO
$-38.41 Mln
EBITDA
$-24.17 Mln
Net Profit
$-45.39 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GlucoTrack Inc (GCTK)
| -30.3 | 1.2 | -17.0 | 754.5 | 157.6 | 8.3 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2016
|
2015
|
|---|---|---|---|---|---|---|
|
GlucoTrack Inc (GCTK)
| 1,074.6 | -40.3 | 20.0 | -75.0 | -28.6 | -41.7 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GlucoTrack Inc (GCTK)
|
2.9 | 50.1 | 0.0 | -4.1 | -- | -57.5 | -- | 7.7 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe and the Asia Pacific. It develops GlucoTrack glucose... monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. Read more
GM & VP of Product
Mr. Erez Ben-Zvi
GM & VP of Product
Mr. Erez Ben-Zvi
Headquarters
Or Yehuda
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of GlucoTrack Inc (GCTK) is $2.91 (NASDAQ) as of 13-May-2022 09:30 EDT. GlucoTrack Inc (GCTK) has given a return of 157.58% in the last 3 years.
Since, TTM earnings of GlucoTrack Inc (GCTK) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of GlucoTrack Inc (GCTK) are Rs -- and Rs -- as of 05-Apr-2026.
GlucoTrack Inc (GCTK) has a market capitalisation of $ 50 Mln as on 13-May-2022. As per SEBI classification, it is a Small Cap company.
Before investing in GlucoTrack Inc (GCTK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.